Bioventus (BVS) vs PROCEPT BioRobotics (PRCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bioventus (BVS) has outperformed PROCEPT BioRobotics (PRCT) over the past year, gaining 92.0% versus a loss of 48.3%. Over five years, BVS leads with a -6.4% price change compared with -58.9% for PRCT. PROCEPT BioRobotics is the larger company by market cap ($1.02 billion vs $872.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BVS | PRCT |
|---|---|---|
| Share price | $12.77 | $17.91 |
| Market cap | $872.26M | $1.02B |
| 1-day change | -2.52% | +2.28% |
| YTD return | +71.64% | -43.07% |
| 1-year return | +92.03% | -48.25% |
| 5-year return | -6.38% | -58.89% |
| P/E ratio (TTM) | 16.80 | — |
| Forward P/E | 13.88 | — |
| EPS (TTM) | $0.76 | $-1.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.89 | $38.11 |
| 52-week low | $6.37 | $16.67 |
| Distance from 52-week high | -19.65% | -53.00% |
| Analyst consensus | none | hold |
| Avg. price target upside | +37.82% | +25.18% |
| Average volume | 623.67K | 1.45M |
| Shares outstanding | 68.31M | 56.92M |
| Employees | 950 | 888 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BVS has outperformed PRCT by 140.3 percentage points over the past year.
About Bioventus
BVS stock →Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Healthcare · Medical Devices · 950 employees
About PROCEPT BioRobotics
PRCT stock →PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.
Healthcare · Medical Devices · 888 employees
BVS vs PRCT FAQ
Which is bigger, Bioventus or PROCEPT BioRobotics?
PROCEPT BioRobotics (PRCT) is larger, with a market capitalization of $1.02B compared with $872.26M for Bioventus (BVS).
Which stock has performed better over the past year, BVS or PRCT?
BVS returned +92.03% over the past 12 months, compared with -48.25% for PRCT (price return, excluding dividends). Past performance does not predict future results.
Are Bioventus and PROCEPT BioRobotics in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.